Vinpocetine is a semi-synthetic derivative of the alkaloid vincamine, obtained from the leaves of the Lesser Periwinkle plant (Vinca minor). It is a cerebral vasodilator and neuroprotective agent primarily used for cognitive enhancement and cerebrovascular disorders. It improves cerebral metabolism by enhancing cerebral blood flow and oxygen utilization, and exhibits antioxidant, anti-inflammatory, and anti-platelet effects. In India, it is widely prescribed for symptoms related to cerebral insufficiency.
Adult: 5mg to 10mg, three times daily. Typical starting dose is 5mg TDS. Maximum daily dose is 30mg.
Note: Administer orally with or after food to minimize potential gastric discomfort. Tablet should be swallowed whole with a glass of water. Do not crush or chew. Regular intervals (e.g., every 8 hours) are recommended for consistent effect.
Vinpocetine's primary mechanism involves selective inhibition of calcium-calmodulin-dependent phosphodiesterase type 1 (PDE1), leading to increased intracellular cyclic AMP (cAMP) and cyclic GMP (cGMP) levels. This results in vasodilation of cerebral blood vessels, improved cerebral blood flow, and enhanced neuronal metabolism. It also inhibits voltage-gated sodium channels, reducing neuronal excitotoxicity. It enhances cerebral glucose and oxygen uptake and utilization. Furthermore, it exhibits antioxidant properties by scavenging hydroxyl radicals and inhibiting lipid peroxidation, and has mild antiplatelet effects.
Pregnancy: Category N (Not classified by US FDA). Animal studies show no direct teratogenicity, but safety in human pregnancy is not established. Use is contraindicated unless the potential benefit justifies the potential risk to the fetus.
Driving: May cause dizziness, drowsiness, or blurred vision, especially at initiation of therapy. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Warfarin, Acenocoumarol | Increased risk of bleeding due to additive antiplatelet effect of vinpocetine. Monitor INR closely. | Major |
| Clopidogrel, Aspirin, NSAIDs (e.g., Ibuprofen) | Increased risk of gastrointestinal bleeding and other hemorrhagic events. | Moderate |
| Antihypertensives (e.g., Amlodipine, Losartan) | Additive hypotensive effect. May cause dizziness and postural hypotension. | Moderate |
| Central Nervous System Depressants (e.g., Alprazolam, Clonazepam) | Potential additive sedative effect. May impair alertness. | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) | Theoretical risk of hypertensive crisis; avoid combination. | Major |
Same composition (Vinpocetine (5mg)), different brands: